EGFR-activated myofibroblasts promote metastasis of pancreatic cancer

Gianluca Mucciolo(University of Cambridge), Joaquín Araos Henríquez(University of Cambridge), Muntadher Jihad(University of Cambridge), Sara Pinto Teles(University of Cambridge), Judhell S. Manansala(University of Cambridge), Wenlong Li(University of Cambridge), Sally Ashworth(University of Cambridge), Eloise G. Lloyd(University of Cambridge), Priscilla S.W. Cheng(University of Cambridge), Weike Luo(University of Cambridge), Akanksha Anand(University of Cambridge), Ashley Sawle(University of Cambridge), Anna Piskorz(University of Cambridge), Giulia Biffi(University of Cambridge)
Cancer Cell
December 28, 2023
Cited by 185Open Access
Full Text

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of these heterogeneous cell populations has limited the development of effective treatment strategies. We previously identified transforming growth factor beta (TGF-β) as a main driver of myofibroblastic CAFs (myCAFs). Here, we show that epidermal growth factor receptor/Erb-B2 receptor (EGFR/ERBB2) signaling is induced by TGF-β in myCAFs through an autocrine process mediated by amphiregulin. Inhibition of this EGFR/ERBB2-signaling network in PDAC organoid-derived cultures and mouse models differentially impacts distinct CAF subtypes, providing insights into mechanisms underpinning their heterogeneity. Remarkably, EGFR-activated myCAFs promote PDAC metastasis in mice, unmasking functional significance in myCAF heterogeneity. Finally, analyses of other cancer datasets suggest that these processes might operate in other malignancies. These data provide functional relevance to myCAF heterogeneity and identify a candidate target for preventing tumor invasion in PDAC.


Related Papers

No related papers found

Powered by citation graph analysis